Pharvaris (NASDAQ:PHVS) Shares Down 5.7% – What’s Next?

Pharvaris N.V. (NASDAQ:PHVS) dropped 5.7% during mid-day trading on Monday . The company traded as low as $25.18 and last traded at $24.9650. Approximately 33,270 shares changed hands during trading, a decline of 78% from the average daily volume of 149,388 shares. The stock had previously closed at $26.48.

Analyst Ratings Changes

PHVS has been the topic of several research reports. Bank of America lifted their price target on shares of Pharvaris from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Thursday, December 4th. Wall Street Zen raised shares of Pharvaris from a “sell” rating to a “hold” rating in a research note on Saturday. Guggenheim upped their price target on shares of Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Morgan Stanley increased their price target on shares of Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Finally, Oppenheimer boosted their price objective on shares of Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Thursday, December 4th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.56.

Pharvaris Stock Performance

The company has a 50-day simple moving average of $24.81 and a two-hundred day simple moving average of $22.88. The firm has a market capitalization of $1.38 billion, a P/E ratio of -7.49 and a beta of -2.79.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.08. As a group, research analysts forecast that Pharvaris N.V. will post -2.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Pharvaris during the second quarter worth approximately $57,000. JPMorgan Chase & Co. raised its position in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Pharvaris in the 3rd quarter valued at $75,000. Public Employees Retirement System of Ohio raised its position in Pharvaris by 39.3% during the third quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock worth $156,000 after acquiring an additional 1,769 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after acquiring an additional 1,695 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.